Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist

Vincent H. Gattone, Xiaofang Wang, Peter C Harris, Vicente Torres

Research output: Contribution to journalArticle

426 Citations (Scopus)

Abstract

The polycystic kidney diseases (PKDs) are a group of genetic disorders causing significant renal failure and death in children and adults. There are no effective treatments. Two childhood forms, autosomal recessive PKD (ARPKD) and nephronophthisis (NPH), are characterized by collecting-duct Cysts. We used animal models orthologous to the human disorders to test whether a vasopressin V2 receptor (VPV2R) antagonist, OPC31260, would be effective against early or established disease. Adenosine-3′,5′-cyclic monophosphate (cAMP) has a major role in cystogenesis, and the VPV2R is the major cAMP agonist in the collecting duct. OPC31260 administration lowered renal cAMP, inhibited disease development and either halted progression or caused regression of established disease. These results indicate that OPC31260 may be an effective treatment for these disorders and that clinical trials should be considered.

Original languageEnglish (US)
Pages (from-to)1323-1326
Number of pages4
JournalNature Medicine
Volume9
Issue number10
DOIs
StatePublished - Oct 2003

Fingerprint

Vasopressin Receptors
Disease Progression
Kidney
Autosomal Recessive Polycystic Kidney
Polycystic Kidney Diseases
Inborn Genetic Diseases
Ducts
Adenosine
Renal Insufficiency
Cysts
Animal Models
Clinical Trials
Therapeutics
Animals
Antidiuretic Hormone Receptor Antagonists

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. / Gattone, Vincent H.; Wang, Xiaofang; Harris, Peter C; Torres, Vicente.

In: Nature Medicine, Vol. 9, No. 10, 10.2003, p. 1323-1326.

Research output: Contribution to journalArticle

@article{5e6c065aee2f46748386839450301f85,
title = "Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist",
abstract = "The polycystic kidney diseases (PKDs) are a group of genetic disorders causing significant renal failure and death in children and adults. There are no effective treatments. Two childhood forms, autosomal recessive PKD (ARPKD) and nephronophthisis (NPH), are characterized by collecting-duct Cysts. We used animal models orthologous to the human disorders to test whether a vasopressin V2 receptor (VPV2R) antagonist, OPC31260, would be effective against early or established disease. Adenosine-3′,5′-cyclic monophosphate (cAMP) has a major role in cystogenesis, and the VPV2R is the major cAMP agonist in the collecting duct. OPC31260 administration lowered renal cAMP, inhibited disease development and either halted progression or caused regression of established disease. These results indicate that OPC31260 may be an effective treatment for these disorders and that clinical trials should be considered.",
author = "Gattone, {Vincent H.} and Xiaofang Wang and Harris, {Peter C} and Vicente Torres",
year = "2003",
month = "10",
doi = "10.1038/nm935",
language = "English (US)",
volume = "9",
pages = "1323--1326",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist

AU - Gattone, Vincent H.

AU - Wang, Xiaofang

AU - Harris, Peter C

AU - Torres, Vicente

PY - 2003/10

Y1 - 2003/10

N2 - The polycystic kidney diseases (PKDs) are a group of genetic disorders causing significant renal failure and death in children and adults. There are no effective treatments. Two childhood forms, autosomal recessive PKD (ARPKD) and nephronophthisis (NPH), are characterized by collecting-duct Cysts. We used animal models orthologous to the human disorders to test whether a vasopressin V2 receptor (VPV2R) antagonist, OPC31260, would be effective against early or established disease. Adenosine-3′,5′-cyclic monophosphate (cAMP) has a major role in cystogenesis, and the VPV2R is the major cAMP agonist in the collecting duct. OPC31260 administration lowered renal cAMP, inhibited disease development and either halted progression or caused regression of established disease. These results indicate that OPC31260 may be an effective treatment for these disorders and that clinical trials should be considered.

AB - The polycystic kidney diseases (PKDs) are a group of genetic disorders causing significant renal failure and death in children and adults. There are no effective treatments. Two childhood forms, autosomal recessive PKD (ARPKD) and nephronophthisis (NPH), are characterized by collecting-duct Cysts. We used animal models orthologous to the human disorders to test whether a vasopressin V2 receptor (VPV2R) antagonist, OPC31260, would be effective against early or established disease. Adenosine-3′,5′-cyclic monophosphate (cAMP) has a major role in cystogenesis, and the VPV2R is the major cAMP agonist in the collecting duct. OPC31260 administration lowered renal cAMP, inhibited disease development and either halted progression or caused regression of established disease. These results indicate that OPC31260 may be an effective treatment for these disorders and that clinical trials should be considered.

UR - http://www.scopus.com/inward/record.url?scp=0142073812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142073812&partnerID=8YFLogxK

U2 - 10.1038/nm935

DO - 10.1038/nm935

M3 - Article

VL - 9

SP - 1323

EP - 1326

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 10

ER -